Concepedia

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

John B. Buse, Michael A. Nauck, Thomas Först, Wayne H.-H. Sheu, Sylvia Shenouda, Cory R. Heilmann, Byron J. Hoogwerf, Aijun Gao, Mark Fineman, Lisa A. Porter,

The Lancet · 2012 · 563 citations · 26 references

DOI

Concepts

References

26

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

Aram V. Chobanian · JAMA · 2003 · 25.6K citations

, , +17

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

Aram V. Chobanian, George L. Bakris, Henry R. Black et al. · Hypertension · 2003 · 13.3K citations

, , +17

The PHQ-8 as a measure of current depression in the general population

Kurt Kroenke, Tara W. Strine, Robert L. Spitzer et al. · Journal of Affective Disorders · 2008 · 5.2K citations

, , +12

Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes

Ralph A. DeFronzo, Robert E. Ratner, Jenny Han et al. · Diabetes Care · 2005 · 1.6K citations

, , +11

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

John B. Buse, Julio Rosenstock, Giorgio Sesti et al. · The Lancet · 2009 · 1.5K citations

, , +13